Clinical experience with combination chemo-/immunotherapy using trabectedin and nivolumab for advanced soft tissue sarcoma.

Chawla, Sant P.; Sankhala, Kamalesh; Ravicz, Joshua R.; Kang, Grace; Liu, Seiya; Stumpf, Nathan; Leong, Bryan; Kim, Seth; Arasheben, Susan; Tseng, William W.; Gordon, Erlinda M.

doi:10.1200/jco.2018.36.15_suppl.e23568

Cited by 13 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among 79 patients enrolled in the phase II study, there was a DCR of 87.3% (6 CR, 14 PR, 49 SD), with a median PFS of 6.7 months and a median OS of 24.6 months [ 94 ]. A retrospective study of nivolumab alone combined with trabectedin in 28 pre-treated STS found a DCR of 72.7% (4 PR and 12 SD among 22 assessable patients), with a median PFS at 6 months of 68.2% [ 154 ].…”

Section: Immunotherapy For Sarcoma: Clinical Resultsmentioning

confidence: 99%

Current Landscape of Immunotherapy for Advanced Sarcoma

Albarrán

Villamayor

Pozas

et al. 2023

Cancers

View full text Add to dashboard Cite

There is substantial heterogeneity between different subtypes of sarcoma regarding their biological behavior and microenvironment, which impacts their responsiveness to immunotherapy. Alveolar soft-part sarcoma, synovial sarcoma and undifferentiated pleomorphic sarcoma show higher immunogenicity and better responses to checkpoint inhibitors. Combination strategies adding immunotherapy to chemotherapy and/or tyrosine–kinase inhibitors globally seem superior to single-agent schemes. Therapeutic vaccines and different forms of adoptive cell therapy, mainly engineered TCRs, CAR-T cells and TIL therapy, are emerging as new forms of immunotherapy for advanced solid tumors. Tumor lymphocytic infiltration and other prognostic and predictive biomarkers are under research.

show abstract

Section: Immunotherapy For Sarcoma: Clinical Resultsmentioning

confidence: 99%

Current Landscape of Immunotherapy for Advanced Sarcoma

Albarrán

Villamayor

Pozas

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…It has been demonstrated that trabectedin with radiation is effective in soft tissue sarcomas [14]. However, trabectedin and immunotherapy may be synergistic in sarcomas [15][16][17].…”

Section: Case Reports In Oncologymentioning

confidence: 99%

Objective Responses in Metastatic Pleomorphic Rhabdomyosarcoma Treated with Combination of Doxorubicin and Pembrolizumab: A Case Series

Kournoutas,

Monga,

Davick

et al. 2024

Case Rep Oncol

View full text Add to dashboard Cite

Introduction: Pleomorphic rhabdomyosarcoma is a rare subtype of rhabdomyosarcoma, a soft tissue sarcoma with skeletal muscle differentiation. Although rhabdomyosarcoma is typically seen in the pediatric population, the pleomorphic variant most frequently presents in adulthood and is characteristically aggressive with no currently established treatment regimen in the setting of metastatic disease. There has been growing interest in the application of immune checkpoint inhibitors alongside conventional chemotherapeutic agents in the treatment of pleomorphic rhabdomyosarcoma. Case Presentation: In the present case series, we report 2 patients with metastatic pleomorphic rhabdomyosarcoma treated with combination doxorubicin and pembrolizumab who had confirmed objective responses. Of note, these 2 patients had variable PD-L1 status – negative and low positive. Duration of treatment response was notable at 14 months and 9 months, respectively, with the first patient remaining on maintenance pembrolizumab therapy and the second patient subsequently achieving complete response with third-line trabectedin. Both patients are currently undergoing routine interval imaging with no evidence of disease at this time. Conclusion: This report highlights and discusses the potential role of PD-1 blockade in the treatment of pleomorphic rhabdomyosarcoma and also discusses burgeoning immunological data that may explain the clinical responses seen in these 2 cases.

show abstract

“…For instance, a Phase II multicentric trial assessing the association of pembrolizumab with metronomic cyclophosphamide in 57 STS patients had only one significant response (solitary fibrous tumor) and a median PFS of only 1.4 months in all patient subgroups [22]. Chawla et al analyzed retrospectively the combination of trabectedin, an alkylating agent approved in the second-line therapy of metastatic STS, to nivolumab in 28 STS patients with an ORR of 18.2%, a median PFS of >45.5 weeks and a median OS of 91 weeks [23]. However, the first successful data were reported with the IMMUNOSARC trial, a Phase I/II trial conducted to evaluate the synergistic activity of nivolumab and sunitinib, anti-VEGF inhibitor, in STS patients.…”

Section: Editorial Assimentioning

confidence: 99%